Form 4: MBX Biosciences Insider Transactions: Chang Carmen Reports Conversion and Stock Purchase

Carmen Chang, a director and 10% owner of MBX Biosciences, reports the conversion of preferred stock to common stock and a purchase of 500,000 shares at $16 per share.

Summary

• Carmen Chang, a director and significant shareholder of MBX Biosciences, filed a Form 4 detailing changes in beneficial ownership.
• The filing reports the conversion of Series A and Series B Convertible Preferred Stock into common stock immediately prior to the company's IPO on September 16, 2024.
• Specifically, 12,299,854 shares of Series A preferred stock converted into 1,023,103 shares of common stock, and 25,142,840 shares of Series B preferred stock converted into 2,091,383 shares of common stock.
• Chang also purchased 500,000 shares of common stock at a price of $16 per share on the same date.
• Following these transactions, Chang indirectly beneficially owns 3,614,486 shares of common stock.
• The shares are held indirectly through NEA 17, where Chang is a manager of NEA 17 GP, LLC, the sole general partner of NEA Partners 17, L.P., which is the sole general partner of New Enterprise Associates 17, L.P. ('NEA 17').
• Chang disclaims beneficial ownership of the securities held by NEA 17 except to the extent of any pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects standard transactions related to an IPO and insider ownership. The purchase of shares at $16 is a positive sign.

Positives

• The conversion of preferred stock to common stock simplifies the company's capital structure following the IPO.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests with management.

Key Dates